Asset Details
Do you wish to reserve the book?
Epstein-Barr virus nuclear antigen 1-specific CD4^+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Epstein-Barr virus nuclear antigen 1-specific CD4^+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells
Do you wish to request the book?
Epstein-Barr virus nuclear antigen 1-specific CD4^+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Epstein-Barr virus nuclear antigen 1-specific CD4^+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells
2008
Overview
Epstein–Barr virus (EBV) nuclear antigen (EBNA)1 is expressed in every EBV‐infected cell, regardless of the state of EBV infection. Although EBNA1 is thought to be a promising antigen for immunotherapy of all EBV‐associated malignancies, it is less clear whether EBNA1‐specific CD4+ T cells can act as direct effectors. Herein, we investigated the ability of CD4+ T‐cell clones induced with overlapping peptides covering the C‐terminal region of EBNA1, and identified minimal epitopes and their restricted major histocompatibility complex class II molecules. Of these, a novel epitope, EYHQEGGPD, was found to be presented by DRB1*0401, 0403 and 0406. Five CD4+ T‐cell clones recognized endogenously processed and presented antigens on EBV‐transformed lymphoblastoid cell lines (LCL) and one example proved capable of killing EBV‐carrying natural killer (NK) and T‐cell lines derived from patients with chronic active EBV infection (CAEBV). Identification of minimal epitopes facilitates design of peptide‐based vaccines and our data suggest that EBNA1‐specific CD4+ T cells may play roles as direct effectors for immunotherapy targeting EBV‐carrying NK and T‐cell malignancies. (Cancer Sci 2008; 99: 1633–1642)
Publisher
Blackwell Publishing Asia,Blackwell
